This quarter exemplifies a classic biotech growth strategy: investing aggressively ahead of potential product approvals. While current losses are substantial, the foundation being laid - with regulatory submissions for Brensocatib accepted in multiple regions and a strong clinical pipeline progressing - positions Insmed for potential significant revenue expansion if these programs succeed, particularly Brensocatib which appears closest to commercialization.